Edition:
United States

InMed Pharmaceuticals Inc (IN.CD)

IN.CD on Canadian Securities Exchange

0.35CAD
19 Jul 2017
Change (% chg)

-- (--)
Prev Close
$0.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
867,126
52-wk High
$0.96
52-wk Low
$0.07

Summary

Name Age Since Current Position

William Garner

49 2016 Chairman of the Board

Eric Adams

2016 President, Chief Executive Officer, Director

Jeffrey Charpentier

2016 Chief Financial Officer, Corporate Secretary

Alexandra Mancini

2016 Senior Vice President - Clinical and Regulatory Affairs

Abo Mohammed

2015 Chief Medical Officer

Martin Bott

2017 Director

Adam Cutler

2015 Director

Andrew Hull

2016 Director

Biographies

Name Description

William Garner

Dr. William J. Garner, M.D., serves as Chairman of the Board of the Company. He is the founder of EGB Advisors PR LLC, a pharmaceutical commercialization boutique, where he has focused on advancing technologies and companies to significant value inflection points, leading to monetization of assets via licensing, mergers and acquisitions, or initial public offering transactions. Dr. Garner has extensive director-level and executive management experience, including his current appointment as chairman and founder of Update Pharma, and as a director at IGXBio. He has previously served as chief executive officer of Invion Ltd., a clinical-stage anti-inflammatory drug development company that resulted from the merger of a private company he founded, and as a co-founder and director of Del Mar Pharmaceuticals. Dr. Garner brings additional medical affairs experience from his tenure at Hoffmann LaRoche's oncology division. Prior to Roche, Dr. Garner was a health care merchant banker in New York. He has a master of public health from Harvard and earned his MD at New York Medical College. Dr. Garner did residency training in anatomic pathology at Columbia-Presbyterian and is currently a licensed physician in the state of New York.

Eric Adams

Mr. Eric A. Adams is President, Chief Executive Officer, Director of the Company. Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs. He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.

Jeffrey Charpentier

Mr. Jeffrey M. Charpentier, CPA, CA, serves as Chief Financial Officer, Corporate Secretary of the Company. Mr. Charpentier is a veteran of the biopharmaceutical industry with over 25 years of experience. Jeff has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors where he led multiple equity financings, raising in excess of$150Mand concluded a number of corporate partnering/product sale transactions. Jeff previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc. Jeff has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.

Alexandra Mancini

Ms. Alexandra D.J. Mancini, M.Sc., serves as Senior Vice President - Clinical and Regulatory Affairs of the Company. In addition to her activities via her private consulting company True North Synergy, Ms. Mancini has been an executive with several biotech companies, overseeing a wide range of drug development activities. As Sr. VP of Clinical & Regulatory Affairs at Sirius Genomics, her role included identifying and managing external resources for medical expertise in sepsis; clinical data management; and statistical theory, programming and analyses. While at INEX Pharmaceuticals as Sr. VP of Clinical & Regulatory Affairs, Ms. Mancini oversaw Clinical Research, Medical Affairs, Clinical Data Management, Medical Writing, Regulatory Affairs, and Quality Assurance for oncology. She served as VP of Regulatory Affairs at QLT Inc. for oncology and ocular diseases, playing a significant role in the development of VISUDYNE® from the preclinical stage through to its approval as the first drug for age-related macular degeneration. While at QLT, Ms. Mancini also led the regulatory approval process for the anticancer drug PHOTOFRIN® and its associated medical devices, the first drug-device combination product approved by the US Food and Drug Administration. Ms. Mancini has led the data analysis and assimilation, writing, submission and subsequent defense of drug submissions to regulatory agencies around the world, leading to several drug approvals and label extensions. Ms. Mancini holds a Master of Science degree from the University of Toronto. She is also a Visiting Lecturer at the Segal Graduate School of Business,Simon Fraser University.

Abo Mohammed

Dr. Abo Mohammed, M.D., DPM, MFPM, is Chief Medical Officer of the Company. Prior to joining InMed Pharmaceuticals, Dr. Mohammed served as associate medical director at GW Pharmaceuticals, a United Kingdom-based pharmaceutical company specializing in the development of cannabinoid-based prescription medicines. In this role, and others at GW Pharmaceuticals, Dr. Mohammed was involved in the advanced delivery of core clinical research, and was involved in key decision making regarding research and development, and product commercialization. He played a leading role in GW Pharmaceuticals' pharma-covigilance team, where his responsibilities included handling of the company's drug safety data from both clinical trials and postmarketing sources, and general management of safety signals including investigations, reviews and reporting. He is also a consultant to the Nigerian regulatory authority (National Agency for Food and Drug Administration and Control) in the areas of pharma-covigilance, postmarketing surveillance and clinical trials. Prior to joining GW Pharmaceuticals, Dr. Mohammed was with PPD (Pharmaceutical Product Development), a leading global contract research organization providing drug discovery, development, life cycle management and laboratory services. Dr. Mohammed also served as CMO/clinical director in various public health care establishments in Africa from 1996 to November, 2010. Dr. Mohammed received his MD at Ahmadu Bello University, Zaria, Nigeria, followed by an MSc in orthopedics at University College London. Dr. Mohammed achieved a DipPharMed in pharmaceutical medicine at the University of Wales in Cardiff. He is a member of the faculty of pharmaceutical medicine at the Royal College of Physicians of England, the British Association of Pharmaceutical Physicians and the International Society for Pharma-covigilance.

Martin Bott

Mr. Martin Bott serves as Director of the Company. He was VP of Corporate Finance and Investment Banking at Eli Lilly & Company. Mr. Bott brings over 28 years of senior financial and executive leadership to InMed's Board of Directors. Mr. Bott has a Bachelors of Business / Marketing (Cologne, Germany, 1985) and a Master's in International Business Studies (University of South Carolina, 1988). He joined Lilly in 1988 and has held roles of increasing responsibility at their headquarters in Indianapolisas well as affiliates in Switzerland, Germany, and the UK. Prior to his current assignment, Mr. Bott was the CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations. He has been a member of the Lilly CFO Staff since December 2002.

Adam Cutler

Mr. Adam D. Cutler is Director of InMed Pharmaceuticals Inc. Mr. Cutler is currently senior vice-president of corporate affairs at Arbutus Biopharma, and previously was a managing director at The Trout Group LLC and Trout Capital LLC, where he successfully executed financings and advised a wide range of life science companies on investor relations, business development and capital-raising strategy. Mr. Cutler spent almost 12 years as a sell-side analyst with firms including Credit Suisse, Canaccord Genuity, JMP Securities and Bank of America Securities, with prior analytical and consulting experience at The Frankel Group and Ernst & Young, health care consulting. Mr. Cutler holds a BA in economics from Brandeis University.

Andrew Hull

Mr. Andrew Hullh is Director of the Company. He has spanned over thirty years as a corporate executive in the global healthcare and biotechnology industries, including the last fourteen years at Takeda Pharmaceuticals where he currently serves as the Vice President of Global Alliances. Mr. Hull has substantial experience in the pharmaceutical industry, with a focus on strategic partnerships and commercialization of prescription drugs.